EXAS vs PATH
EXACT Sciences Corporation (EXAS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
EXAS currently screens at market cap $20.03B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the EXAS and PATH stock pages for the full models.
Not investment advice.